Related Experiment Video
Updated: May 9, 2026
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
Published on: June 7, 2020
Molecular subtyping of brain metastases and implications for therapy
Jaclyn J Renfrow1, Glenn J Lesser
1Department of Neurosurgery, Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, 7157-1082, USA.
Opinion Statement:
Molecular subtyping of tumors and treatment with specifically targeted therapy is a rapidly developing trend in oncology. Genetic and protein biomarkers impact biological behavior, patient prognosis, and inform treatment options. Select examples include EGFR mutations in primary non-small cell lung cancers, Her2 overexpression in breast cancer, and BRAF mutations in melanoma. Systemic benefit is emphasized in targeted therapies; yet lung cancer, breast cancer, and melanoma comprise the most common diagnoses in patients with brain metastases making the effectiveness of targeted therapies in the treatment and/or prevention of brain metastases relevant.Emerging evidence suggests efficacy for targeted therapy in the setting of brain metastases. Randomized, phase III clinical trials indicate targeted HER2 treatment with lapatinib and capecitabine in brain metastases from breast cancer increases the time to progression and decreases the frequency of CNS involvement at progression. Phase II trials and retrospective reviews for gefitinib and erlotinib demonstrate these agents may have a role in both the chemoprevention of brain metastases and, in combination with WBRT, treatment for non-small cell lung cancer (NSCLC) brain metastases. Dabrafenib and other BRAF inhibitors have demonstrated improved survival in patients with brain metastases from melanoma in a recent phase II clinical trial. Further data that support the use of these agents are the subject of several active clinical trials. Challenges and future directions for targeted therapies in brain metastases include both better characterization and drug design with respect to central nervous system distribution. Limited published data demonstrate suboptimal CNS distribution of currently available targeted chemotherapeutic agents. Increasing systemic dosing, alternate delivery methods, and new compounds with improved CNS distribution are being pursued. Additionally, eventual resistance to targeted therapies poses a challenge; however, research is showing resistance mutations are conserved and relatively predictable creating opportunities for second-line therapies with additional targeted drugs. Newer targeted therapies represent an additional chemotherapeutic option for the treatment and/or prevention of brain metastases in patients with an appropriate molecular profile.
Insights
Targeted therapies show promise for treating and preventing brain metastases in lung cancer, breast cancer, and melanoma. Further research is needed to optimize drug delivery and overcome resistance for these advanced cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Molecular subtyping and targeted therapies are revolutionizing cancer treatment.
- Biomarkers like EGFR, Her2, and BRAF guide treatment decisions.
- Brain metastases are common in lung, breast, and melanoma cancers.
Purpose of the Study:
- To review the efficacy of targeted therapies in the treatment and prevention of brain metastases.
- To highlight emerging evidence and ongoing research in this field.
- To discuss challenges and future directions for CNS-targeted cancer therapy.
Main Methods:
- Review of randomized clinical trials (Phase III, Phase II) and retrospective studies.
- Analysis of data on targeted agents such as lapatinib, capecitabine, gefitinib, erlotinib, and dabrafenib.
- Examination of challenges including CNS distribution and drug resistance.
Main Results:
- Targeted HER2 therapy improved progression-free survival in breast cancer brain metastases.
- Gefitinib and erlotinib show potential in preventing and treating non-small cell lung cancer brain metastases.
- BRAF inhibitors like dabrafenib improved survival in melanoma brain metastases.
Conclusions:
- Targeted therapies are a viable option for treating and preventing brain metastases in select cancer patients.
- Optimizing CNS drug distribution and developing strategies to overcome resistance are crucial for future advancements.
- Ongoing clinical trials are essential to further validate and expand the use of targeted agents for brain metastases.
